Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Phase 1
Recruiting
- Conditions
- Locally Advanced/Metastatic Solid Tumors
- Interventions
- Drug: PE0116&PE0105
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05801237
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05800249
- Locations
- 🇨🇳
复旦大学附属中山医院, Shanghai, China
HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT04914351
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Orlando, Florida, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Texas Oncology, Tyler, Texas, United States
News
No news found